Treatment of cardiac fibrosis : from neuro-hormonal inhibitors to CAR-T cell therapy

Paolo Morfino, Alberto Aimo, Vincenzo Castiglione, Carolina Gálvez-Montón, Michele Emdin, Antoni Bayés-Genís

Producció científica: Contribució a revistaArticleRecercaAvaluat per experts

29 Cites (Scopus)

Resum

Cardiac fibrosis is characterized by the deposition of extracellular matrix proteins in the spaces between cardiomyocytes following both acute and chronic tissue damage events, resulting in the remodeling and stiffening of heart tissue. Fibrosis plays an important role in the pathogenesis of many cardiovascular disorders, including heart failure and myocardial infarction. Several studies have identified fibroblasts, which are induced to differentiate into myofibroblasts in response to various types of damage, as the most important cell types involved in the fibrotic process. Some drugs, such as inhibitors of the renin-angiotensin-aldosterone system, have been shown to be effective in reducing cardiac fibrosis. There are currently no drugs with primarily anti-fibrotic action approved for clinical use, as well as the evidence of a clinical efficacy of these drugs is extremely limited, despite the numerous encouraging results from experimental studies. A new approach is represented by the use of CAR-T cells engineered in vivo using lipid nanoparticles containing mRNA coding for a receptor directed against the FAP protein, expressed by cardiac myofibroblasts. This strategy has proved to be safe and effective in reducing myocardial fibrosis and improving cardiac function in mouse models of cardiac fibrosis. Clinical studies are required to test this novel approach in humans.
Idioma originalAnglès
Pàgines (de-a)0001-15
Nombre de pàgines15
RevistaHeart Failure Reviews
DOIs
Estat de la publicacióPublicada - 2022

Fingerprint

Navegar pels temes de recerca de 'Treatment of cardiac fibrosis : from neuro-hormonal inhibitors to CAR-T cell therapy'. Junts formen un fingerprint únic.

Com citar-ho